Screener / SEC EDGAR /CIK 0001582313 /10-K filed Feb 26, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Xenon Pharmaceuticals Inc. XENE

Compare with peers Embed
FY2025 at a glance

Free cash flow down to -$279.9M

XBRL, from each 10-K
RevenueStatements
$7.5M from $0 in FY2024
FY2016FY2025
Net incomeStatements
-$345.9M from -$234.3M in FY2024
FY2016FY2025
Free cash flowStatements
-$279.9M from -$184.5M in FY2024
FY2016FY2025
EPS (diluted)Statements
$-4.36 from $-3.01 in FY2024
FY2016FY2025
Operating marginStatements
-4974.3%
FY2016FY2025

The latest figures

Price and key numbers

From EDGAR
All key numbers (33)
EPS (ttm)
-4.69
Sales (ttm)
0
Net income (ttm)
-428.7M
Sales growth
-
EPS growth
-
Sales Q/Q
-
Free cash flow
-357.1M
Gross margin
-
Oper. margin
n/m
Net margin
n/m
FCF margin
-
R&D / sales
4012.5%
Dividend
-
Debt/Eq
-
Curr. ratio
21.19
Cash
82.6M
Op. cash flow (ttm)
-356.1M
EBITDA
-370.5M
EBITDA margin
n/m
Quick ratio
21.19
FCF after stock pay
-333.6M
Stock pay / sales
716.1%
Shares out.
98.3M
Shares Y/Y
+1.7%
Book / share
11.66
Cash / share
0.84
Sales / share
0.00
Asset turnover
0.00
Days sales out.
71
Sales 3Y CAGR
-7.4%
Sales 5Y CAGR
-25.3%

Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.

Revenue and net income, FY2016 to FY2025

Each fiscal year from its own 10-K · XBRL

Revenue 7.5M +19.5% a year Net income -345.9M
FY2016 revenue 1.8M · Revenues, 0001564590-18-004750 FY2016 net income -23.0M · NetIncomeLoss, 0001564590-18-004750 1.8M FY2016 FY2017 revenue 311K · RevenueFromContractWithCustomerExcludingAssessedTax, 0001564590-19-006514 FY2017 net income -30.7M · NetIncomeLoss, 0001564590-19-006514 311K FY2017 FY2019 revenue 6.8M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001564590-21-009905 FY2019 net income -41.6M · NetIncomeLoss, 0001564590-21-009905 6.8M FY2019 FY2020 revenue 32.2M · RevenueFromContractWithCustomerIncludingAssessedTax, 0000950170-23-005582 FY2020 net income -28.8M · NetIncomeLoss, 0000950170-23-005582 32.2M FY2020 FY2021 revenue 18.4M · RevenueFromContractWithCustomerIncludingAssessedTax, 0000950170-24-023177 FY2021 net income -78.9M · NetIncomeLoss, 0000950170-24-023177 18.4M FY2021 FY2022 revenue 9.4M · RevenueFromContractWithCustomerIncludingAssessedTax, 0000950170-25-029149 FY2022 net income -125.4M · NetIncomeLoss, 0000950170-25-029149 9.4M FY2022 FY2023 revenue 0 · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-26-076650 FY2023 net income -182.4M · NetIncomeLoss, 0001193125-26-076650 0 FY2023 FY2024 revenue 0 · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-26-076650 FY2024 net income -234.3M · NetIncomeLoss, 0001193125-26-076650 0 FY2024 FY2025 revenue 7.5M · RevenueFromContractWithCustomerIncludingAssessedTax, 0001193125-26-076650 FY2025 net income -345.9M · NetIncomeLoss, 0001193125-26-076650 7.5M FY2025

From XBRL in each 10-K. Hover a bar for the line item and filing. "A year" is the steady yearly growth from FY2016 to FY2025 (8 years).

Growth per share, FY2015 to FY2025

Earnings, book value and free cash flow for each diluted share · 10-K XBRL, every year linked to its filing

Average yearly growth
Book value per share +8.2% a year FY2020 $4.96 to FY2025 $7.34, 5 years
Fiscal year toEPS (diluted)Book value / shareFree cash flow / share
Dec 31, 2025 -$4.36$7.34-$3.53
Dec 31, 2024 -$3.01$9.69-$2.37
Dec 31, 2023 -$2.73$13.87-$2.34
Dec 31, 2022 -$2.06$11.92-$1.72
Dec 31, 2021 -$1.77$12.61-$1.64
Dec 31, 2020 -$0.81$4.96-$1.47
Dec 31, 2019 ---
Dec 31, 2018 -$1.63$5.32-$1.81
Dec 31, 2017 -$1.72$2.00-$1.61
Dec 31, 2016 -$1.48$4.12-$1.28
Dec 31, 2015 -$1.10$4.27-$1.31

Per share means per diluted weighted-average share of the same fiscal year (the count under diluted EPS, put on today's share count after a split). Book value is shareholders' equity at the year end, including any preferred stock; free cash flow is operating cash flow less capital spending. Each tile's rate is the steady yearly growth from the first to the last year it names: the window starts at the oldest year, up to ten years back, with a value above zero.

What the balance sheet holds, per share

Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used

Net current asset value, FY2025, in dollars
  • + Current assets $560.6M
  • − All liabilities $51.4M
  • = Net current asset value $509.2M
Per share, year by year
Tangible book value, FY2025, in dollars
  • + Shareholders' equity $581.8M
  • = Tangible book value $581.8M
Per share, year by year

Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.

XENE against Health care peers

Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.

Ten years, side by side
Return on equity
-5.2%18.5%
-37.4%128th of 144 · median 9.2%
XENE and the 5 peers closest in revenue
CompanyRevenue (ttm)Sales growthFYGross marginttmNet marginttmROEttmFCF marginttmDebt / equitylatest
XENE Xenon Pharmaceuticals Inc.$0 ----37.4%--
ROIV Roivant Sciences Ltd.$41.1M -71.6%--838.2%-8.6%-81.2%-
IDYA IDEAYA Biosciences, Inc.$36.5M ----38.5%-957.4%-
CRSP CRISPR Therapeutics AG$25.2M -90.6%---27.7%-0.36
CGON CG Oncology, Inc.$6.2M +255%---24.0%-0.00
SRRK Scholar Rock Holding Corp$570K -----1.16
All 162 companies in the group

Where the return on equity comes from

DuPont: net margin × asset turnover × leverage, FY2025 against FY2020 · 10-K XBRL, year-end balances

Return on equity -59.5% FY2020: -16.8% net income ÷ equity
Net margin -4612.1% FY2020: -89.7% profit per $ of sales: -345.9M ÷ 7.5M
Asset turnover 0.01× FY2020: 0.17× sales per $ of assets: 7.5M ÷ 633.2M
Leverage 1.09× FY2020: 1.10× assets per $ of equity: 633.2M ÷ 581.8M

The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.

Profitability

  • Net margin below the peer median
    -4612.1% vs 6.8%
  • Return on equity below 15%
    -37.4%
  • A profit in 0 of 9 years
Net margin, FY2016 to FY2025: -1275.5% to -4612.1%

Cash and shareholders

  • Free cash flow positive in 0 of 9 years
    −$279.9M last year
  • Share count up over 5 years
    +129.4%
Free cash flow, FY2016 to FY2025: -19.8M to -279.9M

Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.

Income statement, balance sheet and cash flow

Statements · XBRL, each 10-K and 10-Q

From EDGAR

XENE's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.

Revenue7.5M
FY2016: 1.8MFY2017: 311KFY2018: -FY2019: 6.8MFY2020: 32.2MFY2021: 18.4MFY2022: 9.4MFY2023: 0FY2024: 0FY2025: 7.5M FY2017FY2019FY2021FY2023FY2025
Net income-345.9M
FY2016: -23.0MFY2017: -30.7MFY2018: -34.5MFY2019: -41.6MFY2020: -28.8MFY2021: -78.9MFY2022: -125.4MFY2023: -182.4MFY2024: -234.3MFY2025: -345.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow-279.9M
FY2016: -19.8MFY2017: -29.0MFY2018: -35.2MFY2019: -6.0MFY2020: -50.8MFY2021: -71.6MFY2022: -103.9MFY2023: -156.7MFY2024: -184.5MFY2025: -279.9M FY2017FY2019FY2021FY2023FY2025
Free cash flow after stock pay-333.6M
FY2016: -22.0MFY2017: -31.3MFY2018: -37.9MFY2019: -8.9MFY2020: -56.4MFY2021: -81.6MFY2022: -124.3MFY2023: -189.1MFY2024: -235.2MFY2025: -333.6M FY2017FY2019FY2021FY2023FY2025
EPS (diluted)-4.36
FY2016: -1.48FY2017: -1.72FY2018: -1.63FY2019: -1.54FY2020: -0.81FY2021: -1.77FY2022: -2.06FY2023: -2.73FY2024: -3.01FY2025: -4.36 FY2017FY2019FY2021FY2023FY2025
Diluted shares79.3M
FY2016: 15.5MFY2017: 18.0MFY2018: 19.4MFY2019: -FY2020: 34.5MFY2021: 43.6MFY2022: 60.5MFY2023: 66.9MFY2024: 77.9MFY2025: 79.3M FY2017FY2019FY2021FY2023FY2025

Income statement

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue1.8M311K-6.8M32.2M18.4M9.4M007.5M
R&D19.8M25.6M23.6M38.8M50.5M75.5M105.8M167.5M210.4M300.9M
SG&A6.8M7.3M8.4M10.8M12.9M22.0M32.8M46.5M68.9M79.6M
Operating income-24.8M-32.6M-38.0M-42.8M-31.3M-79.0M-129.1M-214.1M-279.3M-373.1M
Interest expense--1.4M1.4M484K00---
Pretax income---34.5M-41.6M-29.1M-78.9M-125.3M-182.7M-238.4M-344.9M
Income tax---24K-23K-257K-6K118K-292K-4.1M1.0M
Net income-23.0M-30.7M-34.5M-41.6M-28.8M-78.9M-125.4M-182.4M-234.3M-345.9M
EPS (diluted)-1.48-1.72-1.63-1.54-0.81-1.77-2.06-2.73-3.01-4.36
Diluted shares15.5M18.0M19.4M-34.5M43.6M60.5M66.9M77.9M79.3M
Depreciation & amortization864K649K586K429K644K906K1.4M2.1M2.6M2.5M
EBITDA-24.0M-31.9M-37.5M-42.4M-30.7M-78.1M-127.7M-212.0M-276.7M-370.5M
Operating margin-1376.4%-10474.3%--627.0%-97.3%-428.4%-1368.9%---4974.3%
Net margin-1275.5%-9872.7%--609.1%-89.7%-427.8%-1328.9%---4612.1%
Revenue growth-88.4%-82.8%--+371%-42.7%-48.8%-100%--

Cash flow

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Operating cash flow-19.6M-28.7M-34.7M-4.7M-48.1M-69.5M-101.0M-151.1M-181.4M-279.1M
Capital spending279K315K507K1.2M2.6M2.0M2.9M5.6M3.1M799K
Free cash flow-19.8M-29.0M-35.2M-6.0M-50.8M-71.6M-103.9M-156.7M-184.5M-279.9M
Stock-based pay (added back)2.2M2.2M2.6M2.9M5.7M10.0M20.4M32.4M50.7M53.7M
Free cash flow after stock pay-22.0M-31.3M-37.9M-8.9M-56.4M-81.6M-124.3M-189.1M-235.2M-333.6M
Debt raised-6.9M8.5M-------
Investing cash flow-47.8M24.3M-29.0M-66.2M-16.8M-246.8M-293.4M-111.4M165.0M218.0M
Financing cash flow24.0M7.1M111.6M27.5M85.8M447.5M278.5M353.5M12.1M117.1M

Stock-based pay and leases

From EDGAR
FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Stock-based pay (expense)2.2M2.2M2.6M2.9M5.7M10.0M20.4M32.4M50.7M53.7M
Stock-based pay / revenue119.9%719.0%-42.8%17.6%54.3%216.0%--716.1%
Operating lease cost---436K536K591K1.1M1.6M1.6M1.6M
Operating lease cash paid--624K634K634K824K919K1.6M1.7M1.7M
Right-of-use assets---933K3.3M8.1M10.4M9.2M7.9M6.6M
Operating lease liabilities---911K3.3M8.3M10.4M10.9M9.0M7.9M

From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.

Sources

Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.

Also

Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/XENE/export.csv") into a cell.

Next:Peers in numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.